(Total Views: 186)
Posted On: 09/18/2020 10:34:52 AM
Post# of 36567
Build, my thought exactly. It's real money (in two weeks). For a company the size of Generex $2.5M should take care of a significant number of bills and/or projects. Of course, this is most likely a "silo" payment, so it has to be used for NGIO initiatives.
Regarding your previous post, the .25 price tag alone should garner interest in GNBT. How long it lasts will depend on follow-up.
BTW, anyone, when might the "milestone" payment be due? What will trigger it, and what might that time frame be? $17.5M is a lot of money.
I like this part, too.
"Bintai will have the right of first refusal for the Ii-Key-SARS-CoV-2 vaccine in Australia, New Zealand, and the global HALAL markets, particularly in Southeast Asia."
If Ii-key is effective, Bintai wants first dibs on selling it to their part of the world.
Regarding your previous post, the .25 price tag alone should garner interest in GNBT. How long it lasts will depend on follow-up.
BTW, anyone, when might the "milestone" payment be due? What will trigger it, and what might that time frame be? $17.5M is a lot of money.
I like this part, too.
"Bintai will have the right of first refusal for the Ii-Key-SARS-CoV-2 vaccine in Australia, New Zealand, and the global HALAL markets, particularly in Southeast Asia."
If Ii-key is effective, Bintai wants first dibs on selling it to their part of the world.
(3)
(0)
